Citation 160507

HALL,IH: LEE,KH: OKANO,M: SIMS,D: IBUKA,T: LIOU,YF: IMAKURA,Y:. (1981). ANTITUMOR AGENTS 42: COMPARISON OF ANTILEUKEMIC ACTIVITY OF HELENALIN, BRUSATOL AND BRUCEANTIN AND THEIR ESTERS ON DIFFERENT STRAINS OF P-388 LYMPHOCYTIC LEUKEMIC CELLS.. 70()

Citation Details

Title	ANTITUMOR AGENTS 42: COMPARISON OF ANTILEUKEMIC ACTIVITY OF HELENALIN, BRUSATOL AND BRUCEANTIN AND THEIR ESTERS ON DIFFERENT STRAINS OF P-388 LYMPHOCYTIC LEUKEMIC CELLS.
Authors	HALL,IH: LEE,KH: OKANO,M: SIMS,D: IBUKA,T: LIOU,YF: IMAKURA,Y:
Year	1981
Volume	70
Issue

Summary

Year: 1981

Journal: Unknown

Organisms and Their Experiments (8)

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	HELENALIN	ACTIVE
2	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	HELENALIN	ACTIVE
3	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	HELENALIN	ACTIVE
4	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	HELENALIN	ACTIVE
5	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	HELENALIN	ACTIVE
6	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	HELENALIN	ACTIVE
7	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN	ACTIVE
8	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN	ACTIVE
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN	INACTIVE
10	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN	ACTIVE
11	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN	ACTIVE
12	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(HELENALINYL)-MALONATE	ACTIVE
2	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(HELENALINYL)-MALONATE	ACTIVE
3	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(HELENALINYL)-MALONATE	ACTIVE
4	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(HELENALINYL)-MALONATE	ACTIVE
5	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(HELENALINYL)-MALONATE	ACTIVE
6	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(HELENALINYL)-MALONATE	ACTIVE
7	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(HELENALINYL)-MALONATE	ACTIVE
8	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(HELENALINYL)-MALONATE	ACTIVE
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(HELENALINYL)-MALONATE	INACTIVE
10	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(HELENALINYL)-MALONATE	ACTIVE
11	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(HELENALINYL)-MALONATE	ACTIVE
12	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(HELENALINYL)-MALONATE	INACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	ACTIVE
2	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	ACTIVE
3	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	ACTIVE
4	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	ACTIVE
5	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	ACTIVE
6	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	ACTIVE
7	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUSATOL	ACTIVE
8	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUSATOL	ACTIVE
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUSATOL	ACTIVE
10	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUSATOL	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUSATOLYL)-MALONATE	ACTIVE
2	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUSATOLYL)-MALONATE	ACTIVE
3	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUSATOLYL)-MALONATE	ACTIVE
4	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUSATOLYL)-MALONATE	ACTIVE
5	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUSATOLYL)-MALONATE	ACTIVE
6	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUSATOLYL)-MALONATE	ACTIVE
7	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(BRUSATOLYL)-MALONATE	ACTIVE
8	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(BRUSATOLYL)-MALONATE	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUSATOLYL)-SUCCINATE	ACTIVE
2	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUSATOLYL)-SUCCINATE	ACTIVE
3	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUSATOLYL)-SUCCINATE	ACTIVE
4	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUSATOLYL)-SUCCINATE	ACTIVE
5	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUSATOLYL)-SUCCINATE	ACTIVE
6	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUSATOLYL)-SUCCINATE	ACTIVE
7	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(BRUSATOLYL)-SUCCINATE	ACTIVE
8	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(BRUSATOLYL)-SUCCINATE	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	ACTIVE
2	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	ACTIVE
3	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	ACTIVE
4	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	ACTIVE
5	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	ACTIVE
6	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	ACTIVE
7	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUCEANTIN	ACTIVE
8	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUCEANTIN	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUCEANTINYL)-MALONATE	ACTIVE
2	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUCEANTINYL)-MALONATE	ACTIVE
3	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUCEANTINYL)-MALONATE	ACTIVE
4	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUCEANTINYL)-MALONATE	ACTIVE
5	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUCEANTINYL)-MALONATE	ACTIVE
6	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUCEANTINYL)-MALONATE	ACTIVE
7	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(BRUCEANTINYL)-MALONATE	ACTIVE
8	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(BRUCEANTINYL)-MALONATE	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUCEANTINYL)-SUCCINATE	ACTIVE
2	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUCEANTINYL)-SUCCINATE	ACTIVE
3	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUCEANTINYL)-SUCCINATE	ACTIVE
4	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUCEANTINYL)-SUCCINATE	ACTIVE
5	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUCEANTINYL)-SUCCINATE	ACTIVE
6	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BIS-(BRUCEANTINYL)-SUCCINATE	ACTIVE
7	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(BRUCEANTINYL)-SUCCINATE	ACTIVE
8	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(BRUCEANTINYL)-SUCCINATE	ACTIVE

Show SPARQL Queries (1)